Skip to main content
. 2017 Apr 28;8(28):46436–46448. doi: 10.18632/oncotarget.17502

Figure 7. Risk ratios (RR) for other lesions for patients with versus without cellular/fibrocellular crescents.

Figure 7

The numbers of patients with M1 (RR, 1.22; 95% CI, 1.07-1.40; P = 0.003), E1 (RR, 4.83; 95% CI, 3.04-7.66; P < 0.001), S1 (RR, 1.76; 95% CI, 1.11-2.80; P = 0.016), and T1/2 (RR, 2.74; 95% CI, 2.10-3.57; P < 0.001) were significantly larger in the IgAN patients with crescents, with no evidence of heterogeneity in M, E, T (M1, I2 = 24.0%; P = 0.267; E1, I2 = 64.8%; P = 0.059; I2 = 17.4%; P = 0.271), and high heterogeneity in S1 (I2 = 87.4%; P < 0.001). M1 defined as M score > 0.5, E1 defined as any E lesion present, S1 defined as any S lesion present, T1/2 defined as > 25% but < 50% and > 50% T lesion present.